OASIS Mailing List ArchivesView the OASIS mailing list archive below
or browse/search using MarkMail.

 


Help: OASIS Mailing Lists Help | MarkMail Help

etmf-comment message

[Date Prev] | [Thread Prev] | [Thread Next] | [Date Next] -- [Date Index] | [Thread Index] | [List Home]


Subject: Overall comments on OASIS ETMF Standard


Dear OASIS Technical Committee

 

As the Chairman of the TMF Reference Model Steering Committee and the co-Chair of the TMF Reference Model, I am writing to express my overall concern regarding the lack of alignment between the TMF Reference Model and the OASIS eTMF Standard.

 

The TMF Reference model was born out of a DIA special interest group in 2009, and has released versions 1.0, 1.1, 1.2 and 2.0 since then.

 

Number of individuals who have ever been on the TMF Reference Model = 454.

Number of currently members who are part of the ongoing communications= 364

Total number of companies represented since inception = 203

Companies represented listed below:

 

Aastrom

BD

Clinipace

Eli Lilly

Genzyme

ISI

Mcdougall Scientific

Paragon

QC2

Shire

United Therapeutics

Abbott

Biogen Idec

Cognizant

EMA

Gilead

J & J

Medidata

Parexel

Quanticate

Sidley austin

URL Pharma

Abbvie

Bioventus

Consultant

EMC

 

Janssen

Medimmune

Peter MacCallum Cancer Centre

Quintiles

Site - Australia

Veeva

Actelion

Bluebird

Cordis

EMD Serono

Glemser

 

Medi-San

Pfizer

Rammell Consulting

Smith & Nephew (devices)

Vernalis

Adamas Consulting

Boehringer Ingelheim

Corementum

Endocyte

Global Clincial Conenctions

Kanglaite

MedNet Solutions

Pfizer

Regeneron

Solvay

Vertex

Advance research associates

 

Covance

ePharma Solutions

Grunenthal

Kendle

Medtronics

Pharma Compliance

Registrat-MAPI

Spectrum

Wingspan

Akros Pharma

Cadence Pharmaceuticals

CRIX International - Quintiles

Epson & St Helliers NHS Trust

GSK

Kids Research Inst, NSW

Merck

Pharmacovigilant

Riverdale Ass

St Vincents, Melbourne

WIPRO

Alexion

Cambridge Cognition

CSC

eRegulatory Submission

GXPi

Kings College

MHRA

Pharmanet

Roche

Stem Cell Therapeutics

WWCT

Alkermes

CareLex

Cubist Pharmaceuticals

 

Harrison Clinical Research

Kingston Consulting

Millenium

Pharmavigilant

Royal Marsden

Sterling Bio

Xoma

Allergan

CE3

Cytrx

Ethicon / J&J

Helicon Therapeutics

Leo Pharma

Mission 3

Phlexglobal

RQ2

Sunovian

Xybion

Alnara

Celerion

Daiichi-Sankyo

FDA

Highpoint Solutions

Life Sciences Integration Partners

Mitsubishi

Photocure

Sacura

Syntax

Zymogenetics

Amgen

Celgene

Dainippon Sumitoma

Ferring

Human Genome Sciences

Eli Lilly

MMRX

Pierre Fabre

Safe Biopharma

Syntel

 

Antisoma

Centocor

Datatrak

FHI 360

i3 Research

Lorenz

Montrium

Point Consultancy

Sandoz

Takeda

 

Aris Global

Cephalon

Debra Fadil Consulting

 

ICON

Lundbeck

Novo-Nordisk

Pozen

Sanofi Aventis

Target Health

 

Astellas

Cereve

DIA

Fibrogen

IDDI

Lung Rx

NaviGATE

PPD

Sanofi Pasteur

 

 

Astra Zeneca

Chiesi

Duke Clinical Research Institute

Forest

Imclone

Malinkrodt

Nektar

PRA

Santen

Teva

 

Auxilium

Chiesi

DW Associates

Galderma

INC Research

 MSD

Nextdocs

Premier Research

SBC Global

Tournier

 

Bausch & Lomb

Chiltern

eClinical

GE Healthcare

Integrated Submission Strategies

Mapi

Novartis

Prostrakan (IIT)

Sepian

Transperfect

 

Baxter

Circassia

Edetek

Genentech

Intercept

Mass General Hospital

Otsuka

Purdue

Servier

UCB

 

Bayer

Clinilabs

Eisai

Genprobe

Intralinks

Mcdougall Scientific

Orion Pharma

QA Consultant

SGS

Uni of NSW

 

 

 

 

 

 

 

 

 

 

 

 

Based on the above, our level of expertise has to make us the TMF content experts.

 

Please can the content then be aligned to our expert input.

 

Kind regards

 

Karen

 

Description: Description: Phlex-small-png.png

Karen Roy, Chief Business Development Officer, Phlexglobal Ltd
M: +44 (0)7775 708754  DD: +44
(0)1494 720282  T: +44 (0)1494 720420 

E: kroy@phlexglobal.com

W:www.phlexglobal.com  

 

Phlexglobal are worldwide leaders and specialists in the provision of local & global, technology enabled TMF document management solutions and support services.

The information in this E-mail and any attachments to it are confidential in every way and for the sole view of the addressee. If you have received it in error, please accept our apologies and delete it from your system. Thank you. | Any opinions expressed in this message or its attachments are those of the author and are not necessarily those of Phlexglobal Ltd, who disclaim all responsibility and accept no liability for the consequences of anyone acting on the information contained.

Phlexglobal Ltd is a limited company registered in England and Wales under company number 3544670 | VAT No. 108 216 051 | Registered address at Mandeville House, 62 The Broadway, Amersham, Bucks HP7 0HJ, UK

 



[Date Prev] | [Thread Prev] | [Thread Next] | [Date Next] -- [Date Index] | [Thread Index] | [List Home]